Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors Meeting Abstract
| Authors: | Drilon, A.; Besse, B.; Camidge, D. R.; Ou, S. H. I.; Gadgeel, S. M.; Johnson, M. L.; Calles, A.; de Miguel, M. J.; Spira, A. I.; Felip, E.; Lopes, G.; van der Wekken, A. J.; Elamin, Y. Y.; Green, J.; Sun, Y.; Soglia, J.; Zhu, V. W.; Lin, J. J. |
| Abstract Title: | Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors |
| Meeting Title: | 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 174 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Oct 26-28 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S6 |
| End Page: | S7 |
| Language: | English |
| ACCESSION: | WOS:000876973400012 |
| PROVIDER: | wos |
| DOI: | 10.1016/s0959-8049(22)00821-8 |
| Notes: | Meeting Abstract: 8 -- In "Plenary Session 6: New Drugs on the Horizon" -- Source: Wos |
